Bumetanide Injection Shortage: Current Availability and Manufacturer Updates

What’s in Shortage

Bumetanide Injection (brand name: BUMETANIDE) is currently listed on the FDA drug shortage database. This medication is an injection used within the cardiovascular therapeutic category. While the shortage status is listed as “Current,” several manufacturers have recently reported that their specific presentations are available.

This shortage was first posted on January 31, 2018, and the most recent update was provided on February 3, 2026.

Which Manufacturers Are Affected

Several manufacturers supply Bumetanide Injection. Their current status and contact information are as follows:

• Sagent Pharmaceuticals

  • Status: Available
  • Presentations: .25 mg/1 mL (NDC 25021-321-10 and NDC 25021-321-04)
  • Contact: 866-625-1618

• Fresenius Kabi USA, LLC

  • Status: Available (Note: The manufacturer advises checking wholesalers for current inventory)
  • Presentations: .25 mg/1 mL (NDC 65219-570-04 and NDC 65219-572-10)
  • Contact: 888-386-1300

• MSN Laboratories Private Limited (Distributed by Novadoz Pharmaceuticals LLC)

  • Status: Available
  • Presentations: .25 mg/1 mL (NDC 72205-101-07 and NDC 72205-102-07); 0.25 mg/mL in 4 mL (NDC 72205-101-01); 0.25 mg/mL in 10 mL (NDC 72205-102-01)
  • Contact: 855-668-2369 or [email protected]

Why There’s a Shortage

The FDA source data does not provide a specific reason for the ongoing shortage of Bumetanide Injection.

What Patients Should Do

If you or a loved one relies on Bumetanide Injection, please consider the following steps:

• Consult Your Healthcare Provider: Always speak with your doctor regarding your treatment plan. Do not make changes to your medication without professional medical guidance.
• Speak with Your Pharmacist: Pharmacists often have the most up-to-date information on which wholesalers have stock available.
• Contact Manufacturers: If you are having difficulty locating the medication, you may use the contact information provided above to inquire about supply distribution.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for all medical decisions and alternative treatment options.

Source

Information provided by the FDA Drug Shortage Database.